Viatris (VTRS) Stock Price, News & Analysis

Company Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Key Stats

• Today's Range: $8.63 to $8.87
• 50-Day Range: $8.29 to $9.41
• 52-Week Range: $6.85 to $13.55
• Volume: 6.73 million shs
• Average Volume: 7.34 million shs
• Market Capitalization: $10.34 billion
• P/E Ratio: N/A
• Dividend Yield: 5.45%
• Price Target: $10.40
• Consensus Rating: Reduce

Viatris Stock Analysis - MarketRank™

Viatris scored higher than 44% of companies evaluated by MarketBeat, and ranked 601st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Viatris has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on 1 buy rating, 2 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Viatris has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: -4.10%

Earnings Growth

Earnings for Viatris are expected to decrease by -4.10% in the coming year, from $2.68 to $2.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Viatris is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Viatris is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Viatris has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.32% of the float of Viatris has been sold short.

Short Interest Ratio / Days to Cover

Viatris has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Viatris has recently increased by 142.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Viatris is a leading dividend payer. It pays a dividend yield of 5.49%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Viatris does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Viatris will have a dividend payout ratio of 18.68% next year. This indicates that Viatris will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.32% of the float of Viatris has been sold short.

Short Interest Ratio / Days to Cover

Viatris has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Viatris has recently increased by 142.01%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: -0.40

News Sentiment

Viatris has a news sentiment score of -0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Viatris this week, compared to 11 articles on an average week.

Search Interest

Only 12 people have searched for VTRS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

4 people have added Viatris to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Viatris insiders have bought more of their company's stock than they have sold. Specifically, they have bought $536,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.13% of the stock of Viatris is held by insiders.

Percentage Held by Institutions

79.88% of the stock of Viatris is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VTRS Stock Analysis - Frequently Asked Questions

How have VTRS shares performed this year?

Viatris' stock was trading at $12.45 at the beginning of 2025. Since then, VTRS stock has decreased by 29.2% and is now trading at $8.81.

How were Viatris' earnings last quarter?

Viatris Inc. (NASDAQ:VTRS) posted its quarterly earnings results on Thursday, May, 8th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.49 by $0.01. The firm's revenue for the quarter was down 10.9% on a year-over-year basis.
Read the conference call transcript.

Is Viatris doing a stock buyback?

Viatris' board authorized a share buyback program on Wednesday, February 28th 2024, which allows the company to repurchase $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 6.7% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board of directors believes its stock is undervalued.

Who are Viatris' major shareholders?

Viatris' top institutional investors include Assenagon Asset Management S.A. (0.34%), Wedge Capital Management L L P NC (0.29%), Envestnet Asset Management Inc. (0.16%) and Arnhold LLC (0.14%). Insiders that own company stock include Rajiv Malik, Scott Andrew Smith, Anthony Mauro, Paul Campbell, Harry Korman, Brian Roman, Xiangyang (Sean) Ni, Dillon Joellen Lyons, Andrew Cuneo and Der Meer Mohr Pauline Van.
View institutional ownership trends.

How do I buy shares of Viatris?

Shares of VTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Viatris own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Viatris investors own include Pfizer (PFE), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Tesla (TSLA) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 5/08/2025
• Record date for 6/16 Dividend: 5/23/2025
• Ex-Dividend for 6/16 Dividend: 5/23/2025
• Dividend Payable: 6/16/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VTRS
• CIK: 1792044
• Web: www.viatris.com
• Phone: (724) 514-1800
• Fax: 724-514-1870
• Employees: 32,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Viatris: $10.40
• High Price Target: $13.00
• Low Price Target: $9.00
• Potential Upside/Downside: +18.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 3.29
• P/E Growth: N/A
• Net Income: -$634.20 million
• Net Margins: -26.45%
• Pretax Margin: -27.39%
• Return on Equity: 16.20%
• Return on Assets: 7.01%

Debt

• Debt-to-Equity Ratio: 1.02
• Current Ratio: 1.68
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $14.74 billion
• Price / Sales: 0.70
• Cash Flow: $5.15 per share
• Price / Cash Flow: 1.71
• Book Value: $15.61 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 1,173,680,000
• Free Float: 1,172,156,000
• Market Cap: $10.34 billion
• Optionable: Optionable
• Beta: 0.90